Learn more

GRACELL BIOTECHNOLOGIES SHANGHAI CO LTD

Overview
  • Total Patents
    19
  • GoodIP Patent Rank
    88,477
  • Filing trend
    ⇧ 1100.0%
About

GRACELL BIOTECHNOLOGIES SHANGHAI CO LTD has a total of 19 patent applications. It increased the IP activity by 1100.0%. Its first patent ever was published in 2017. It filed its patents most often in China, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and biotechnology are FINNISH NAT PUBLIC HEALTH, SHANGHAI CELL THERAPY RES INST and SHANGHAI UNICAR THERAPY BIO MEDICINE TECH CO LTD.

Patent filings in countries

World map showing GRACELL BIOTECHNOLOGIES SHANGHAI CO LTDs patent filings in countries

Patent filings per year

Chart showing GRACELL BIOTECHNOLOGIES SHANGHAI CO LTDs patent filings per year from 1900 to 2020

Focus industries

Top inventors

# Name Total Patents
#1 Cao Wei 16
#2 Liu Liping 13
#3 Shen Lianjun 9
#4 Yang Chunhui 7
#5 He Jiaping 7
#6 Wang Xinxin 6
#7 Ma Anyun 6
#8 Sun Jing 5
#9 Zhang Yongliang 5
#10 Zhang Hua 5

Latest patents

Publication Filing date Title
WO2020224605A1 Bcma-targeting engineered immune cell and use thereof
WO2020224606A1 Engineered immune cell targeting bcma and use thereof
WO2020151752A1 Engineered immune cells targeting cd20 combination
TW202100747A Compositions and methods for immunotherapy
WO2020088631A1 Compositions and methods for t cell engineering
WO2019063018A1 Engineered immune cell having suicide gene switch and targeting human mesothelin
CN111133101A Engineered immune cells capable of inducing secretion of anti-CD 47 antibody
WO2019047899A1 Universal chimeric antigen receptor t-cell preparation technique
CN110577604A Chimeric antigen receptor T cell carrying GITR costimulatory signal targeting EGFR
CN110577932A Chimeric antigen receptor T cell derived from umbilical cord blood
CN108424461A CD47-CAR-T cells
CN110300603A CD47-CAR-T cell